^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    SGLT-2 inhibitor

    Associations

    News

    Trials
    16h
    Genetics of Response to Canagliflozin (clinicaltrials.gov)
    P1, N=700, Active, not recruiting, University of Maryland, Baltimore | Trial completion date: Sep 2025 --> Dec 2026
    Trial completion date
    17h
    Empagliflozin beyond antidiabetic effect: Amelioration of cyclophosphamide-induced testicular toxicity in rats: Orchestrating klotho/Nrf-2/PPAR-γ/NF-κB/ Bax/Bcl-2 cues. (PubMed, Biochem Pharmacol)
    Furthermore, EMPA enhanced testicular tissue survival by decreasing Bcl-2-associated X (Bax) protein, while elevating B-cell lymphoma 2 (Bcl-2) protein, thus reducing caspase-3 expression. Consequentially, EMPA, through antioxidant, anti-inflammatory, and anti-apoptotic effects, could be nominated as a promising candidate against CP-induced gonadal toxicity.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • TNFA (Tumor Necrosis Factor-Alpha) • HMOX1 (Heme Oxygenase 1) • IL10 (Interleukin 10) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • PPARG (Peroxisome Proliferator Activated Receptor Gamma)
    |
    cyclophosphamide
    19h
    CONTROL: Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin (clinicaltrials.gov)
    P3, N=0, Withdrawn, Eurofarma Laboratorios S.A. | N=408 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Head-to-Head
    |
    metformin
    1d
    CREST-KT: CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, Duke University | N=72 --> 20 | Trial completion date: Aug 2026 --> Jan 2026 | Trial primary completion date: Jul 2026 --> Jan 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    2d
    A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) (clinicaltrials.gov)
    P3, N=120, Recruiting, Boehringer Ingelheim | Not yet recruiting --> Recruiting
    Enrollment open
    3d
    Dapagliflozin alleviates sunitinib-induced cardiotoxicity through AMPKα-PPARα axis and enhances the sensitivity of renal cell carcinoma to sunitinib. (PubMed, BMC Med)
    Our results demonstrate that dapagliflozin not only enhances the antitumor efficacy of sunitinib against renal cell carcinoma but also alleviates sunitinib-induced cardiac toxicity in mice via modulation of the AMPKα-PPARα axis.
    Journal
    |
    PPARA (Peroxisome Proliferator Activated Receptor Alpha)
    |
    sunitinib
    6d
    STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease (clinicaltrials.gov)
    P3, N=420, Not yet recruiting, University of Cologne
    New P3 trial
    7d
    DAPA-ICU: Dapagliflozin for Cardio-renal Protection After ICU Discharge (clinicaltrials.gov)
    P3, N=600, Recruiting, Assistance Publique - Hôpitaux de Paris | Not yet recruiting --> Recruiting | Trial completion date: Oct 2028 --> Jan 2029 | Initiation date: Sep 2025 --> Dec 2025 | Trial primary completion date: Oct 2028 --> Jan 2029
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    8d
    EmFin-Nx: Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT (clinicaltrials.gov)
    P2, N=10, Terminated, Jinling Hospital, China | N=100 --> 10 | Trial completion date: Dec 2027 --> Oct 2025 | Recruiting --> Terminated | Trial primary completion date: Jan 2027 --> Oct 2025; The patient enrollment rate is proceeding too slowly
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    8d
    SGLT2i Therapy in Islet Transplantation (SIT) (clinicaltrials.gov)
    P4, N=40, Not yet recruiting, University of Minnesota | Initiation date: Dec 2025 --> Mar 2026
    Trial initiation date
    9d
    Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome (clinicaltrials.gov)
    P2, N=130, Not yet recruiting, Yale University
    New P2 trial
    9d
    OPTIMAR: Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART) (clinicaltrials.gov)
    P3, N=300, Active, not recruiting, Kirby Institute | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    pitavastatin